ARTICLE | Product Development
Pandemic products are just the start for Pfizer’s vaccine strategy
Pfizer is setting out to prove its vaccine success doesn’t end with COVID-19
November 3, 2022 12:52 AM UTC
The pandemic put Pfizer on the map as the leading vaccine developer, but the pharma isn’t stopping at COVID-19. With a pipeline strategy that weaves pandemic innovations into a set of programs built on established technologies, Pfizer is looking to non-COVID vaccines as future growth drivers.
So far, Pfizer Inc. (NYSE:PFE) is on track in its strategy to expand its non-COVID vaccine business. The company has six candidates in Phase II and III development, giving it the broadest late-stage vaccine pipeline among its pharma peers...